| Literature DB >> 33223825 |
Juliana Souza Uzeloto1, Alessandra Choqueta de Toledo-Arruda2, Bruna Spolador de Alencar Silva1, Marjorie de Assis Golim3, Aline Márcia Marques Braz3, Fabiano Francisco de Lima1, Isis Grigoletto1, Ercy Mara Cipulo Ramos1.
Abstract
Aims: To evaluate the expressions of intracellular cytokines in CD4+ T lymphocytes and to investigate the correlation between biomarker expressions and clinical and functional characteristics of stable COPD patients. Patients andEntities:
Keywords: chronic obstructive pulmonary disease; flow cytometry; inflammation; phenotype
Mesh:
Substances:
Year: 2020 PMID: 33223825 PMCID: PMC7671532 DOI: 10.2147/COPD.S268955
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Figure 1Flowchart of sample selection.
Figure 2Characterization of intracytoplasmic cytokines in helper T lymphocytes. Peripheral blood cell suspension staining with specific monoclonal antibodies Anti-CD3, CD4 (surface) and IL-8, IL-13, IL-17, IL-6, IL-2, IL-10, TNF-ɑ (cytoplasmic). Characterized CD3+/CD4+ T lymphocyte phenotype (dot plots), the expression of intracellular cytokines was evaluated as demonstrated in histograms (negative control - red; expression of cytokine - blue).
Participant Characteristics
| Total Sample (n=36) | GOLD 1 and 2 (n=19) | GOLD 3 and 4 (n=17) | p | Mean Difference (95% CI) | |
|---|---|---|---|---|---|
| Male/Female n (%) | 19 (52.8)/17 (47.2) | 9 (47.4)/10 (52.6) | 10 (58.8)/7 (41.2) | 0.49 | |
| Age (years) | 69.67±7.3 | 69.79±8.05 | 69.53±6.61 | 0.92 | 0.26 (−4.76 to 5.28) |
| Body weight (kg) | 67.12±14.1 | 65.93±15.58 | 68.44±12.57 | 0.60 | −2.51 (−12.17 to 7.16) |
| Height (m) | 1.63±0.09 | 1.60±0.08 | 1.66±0.09 | 0.06 | −0.06 (−0.11 to 0.00) |
| Lung function | |||||
| FEV1 (% of predicted) | 52.81±20.6 | 68.79±13.73 | 34.94±8.56 | <0.001* | 33.85 (25.99 to 41.71) |
| FVC (% of predicted) | 72.42±18.8 | 82.68±15.15 | 60.94±15.8 | <0.001* | 21.74 (11.25 to 32.23) |
| FEV1/FVC (%) | 53.48±11.76 | 61.54±6.35 | 44.46±9.69 | <0.001* | 17.07 (11.58 to 22.56) |
| Dyspnea | |||||
| MRC | 3 (2–4) | 3.5 (2–4) | 3 (2–5) | 0.61 | −0.24 (−1.17 to 0.69) |
| Quality of life | |||||
| CRQ | 19.88±5.11 | 21.16±4.25 | 18.45±5.71 | 0.11 | 2.72 (−0.67 to 6.10) |
| Vital signs | |||||
| SBP (mmHg) | 120.56±15.85 | 121.58±16.42 | 119.41±15.6 | 0.69 | 2.17 (−8.71 to 13.05) |
| DBP (mmHg) | 80 (70–90) | 80 (70–90) | 80 (70–90) | 0.56 | −2.04 (−9.13 to 5.05) |
| HR (beats/minute) | 74.5 (68.25–81.75) | 74 (67–81) | 75 (69.5–82.5) | 0.24 | −4.35 (−11.67 to 2.98) |
| RF (breaths/minute) | 18 (16–20) | 20 (16–20) | 16 (15–20) | 0.75 | 0.39 (−2.11 to 2.89) |
| SpO2 (%) | 94.39±3.24 | 96.05±1.58 | 92.53±3.62 | <0.001* | 3.52 (1.66 to 5.38) |
| Body composition | |||||
| Fat mass (kg) | 24.12±9.56 | 23.69±10.6 | 24.58±8.61 | 0.79 | −0.89 (−7.55 to 5.78) |
| Skeletal muscle mass (kg) | 22.9±4.92 | 22.23±5.15 | 23.61±4.72 | 0.42 | −1.37 (−4.78 to 2.03) |
| Lean mass (kg) | 40.11±7.77 | 38.97±8.08 | 41.32±7.47 | 0.38 | −2.35 (−7.71 to 3.01) |
| Physical activity level | |||||
| Steps per day | 4080.5 (2606.93–5599.21) | 4436.14 (2788.43–6112.71) | 3093.71 (1356.29–4552.41) | 0.03* | 2381.37 (282.51 to 4480.23) |
| Muscle strength | |||||
| Elbow flexors (N) | 87.4 (64.4–123.2) | 82.9 (61.35–115.9) | 104.6 (64.6–127.8) | 0.66 | −6.95 (−38.32 to 24.42) |
| Knee flexors (N) | 124.63±43.5 | 121.36±40.37 | 128.09±47.58 | 0.65 | −6.74 (−37.02 to 23.55) |
| Knee extensors (N) | 162.2 (106.2–223.2) | 166.7 (105.65–205.8) | 155.8 (96.5–228) | 0.64 | 13.75 (−45.17 to 72.67) |
| Functional exercise capacity | |||||
| 6MWT distance (m) | 439.56±123.35 | 480.58±113.13 | 393.71±121.05 | 0.03* | 86.87 (7.55 to 166.20) |
Notes: Data expressed as mean ± standard deviation or median (range 25% −75%), according to normality. *p<0.05 when comparing the ratings by GOLD.
Abbreviations: n, sample size; %, percentage; kg, kilograms; m, meters; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; MRC, Medical Research Council dyspnea scale; CRQ, Chronic Respiratory Questionnaire; SBP, systolic blood pressure; DBP, diastolic blood pressure; mmHg, millimeters of mercury; HR, heart rate; RF, respiration frequency; SpO2, peripheral oxygen saturation; N, newton; 6MWT, six-minute walk test.
Expression of Cytokines in CD4+ T Lymphocytes in the Total Sample and in Subgroups Classified by GOLD
| Total Sample (n=36) | GOLD 1 and 2 (n=19) | GOLD 3 and 4 (n=17) | p | Mean Difference (95% CI) | |
|---|---|---|---|---|---|
| IL-8 (%) | 4.59 (1.82–23.22) | 2.64 (1.5–22.47) | 5.35 (2.82–26.28) | 0.60 | −3.59 (−17.42 to 10.24) |
| IL-13 (%) | 10.14±4.46 | 9.34±4.74 | 11.04±4.09 | 0.26 | −1.69 (−4.71 to 1.32) |
| IL-17 (%) | 0.12 (0.06–0.22) | 0.11 (0.06–0.28) | 0.12 (0.06–0.2) | 0.35 | 0.05 (−0.06 to 0.17) |
| IL-6 (%) | 10.75±5.02 | 10.23±5.25 | 11.32±4.84 | 0.52 | −1.09 (−4.52 to 2.35) |
| IL-2 (%) | 21.18±7.72 | 18.53±6.94 | 24.15±7.66 | 0.03* | −5.61 (−10.55 to −0.67) |
| IL-10 (%) | 0.14 (0.08–0.24) | 0.14 (0.06–0.24) | 0.14 (0.09–0.27) | 0.44 | −0.05 (−0.17 to 0.08) |
| TNF-α (%) | 8.42±3.78 | 8.13±4.56 | 8.75±2.76 | 0.63 | −0.62 (−3.21 to 1.97) |
Notes: Data expressed as mean ± standard deviation or median (range 25% −75%), according to normality. *p<0.05 when comparing the ratings by GOLD.
Abbreviations: IL, interleukin; TNF-α, tumour necrosis factor alpha; %, percentual.
Figure 3Graphical representation of linear regression between cytokine expressions in CD4+ T lymphocytes.
Figure 4Graphical representation of linear regression between cytokine expressions in CD4+ T lymphocytes and clinical and functional characteristics. (A) presents the correlations between CD4+IL-10+ and muscle strength expression; (B) is between CD4+IL-8+ and steps per day and peripheral oxygen saturation; (C) is the correlation between CD4+IL-17+ and FVC (% of predicted).